Your browser is no longer supported. Please, upgrade your browser.
CELG Celgene Corporation monthly Stock Chart
Celgene Corporation
IndexS&P 500 P/E14.63 EPS (ttm)6.58 Insider Own0.10% Shs Outstand705.92M Perf Week2.23%
Market Cap67.94B Forward P/E7.66 EPS next Y12.57 Insider Trans-3.22% Shs Float703.81M Perf Month3.03%
Income4.75B PEG0.81 EPS next Q2.62 Inst Own78.70% Short Float1.63% Perf Quarter6.47%
Sales15.77B P/S4.31 EPS this Y5.90% Inst Trans2.34% Short Ratio1.29 Perf Half Y37.54%
Book/sh11.62 P/B8.28 EPS next Y17.04% ROA13.50% Target Price97.00 Perf Year22.81%
Cash/sh10.90 P/C8.83 EPS next 5Y17.98% ROE83.90% 52W Range58.59 - 97.07 Perf YTD50.18%
Dividend- P/FCF10.20 EPS past 5Y26.80% ROI16.70% 52W High-0.84% Beta1.66
Dividend %- Quick Ratio2.70 Sales past 5Y18.70% Gross Margin96.20% 52W Low64.28% ATR1.08
Employees8852 Current Ratio2.80 Sales Q/Q13.80% Oper. Margin42.40% RSI (14)62.40 Volatility1.15% 1.04%
OptionableYes Debt/Eq2.48 EPS Q/Q94.70% Profit Margin30.10% Rel Volume0.33 Prev Close94.83
ShortableYes LT Debt/Eq2.42 EarningsMay 03 BMO Payout0.00% Avg Volume8.87M Price96.25
Recom2.90 SMA201.38% SMA503.77% SMA20013.31% Volume2,889,957 Change1.50%
May-03-19Downgrade Barclays Overweight → Equal Weight $102
Apr-01-19Downgrade William Blair Outperform → Mkt Perform
Apr-01-19Downgrade UBS Buy → Neutral $94 → $102
Apr-01-19Downgrade Atlantic Equities Overweight → Neutral
Feb-01-19Downgrade Jefferies Buy → Hold $95
Jan-04-19Upgrade Robert W. Baird Neutral → Outperform
Jan-04-19Upgrade Goldman Sell → Neutral
Dec-21-18Resumed BTIG Research Neutral
Oct-01-18Initiated Cantor Fitzgerald Overweight $100
Jun-18-18Upgrade Standpoint Research Hold → Buy
May-29-18Reiterated SunTrust Hold $106 → $96
May-23-18Upgrade Bernstein Mkt Perform → Outperform
May-23-18Downgrade Argus Buy → Hold
May-07-18Downgrade RBC Capital Mkts Top Pick → Outperform
Apr-13-18Resumed Morgan Stanley Equal-Weight $93
Mar-26-18Reiterated Goldman Sell $97 → $85
Mar-21-18Resumed JP Morgan Overweight $110
Feb-28-18Reiterated Stifel Buy $130 → $128
Feb-28-18Downgrade SunTrust Buy → Hold
Feb-13-18Upgrade Barclays Equal Weight → Overweight $105
May-21-19 06:55PM  John Paulson's Top 5 Buys in the 1st Quarter
11:48AM  5 Winning Ideas for a Thinking World, Plus a 5-Stock Sampler Review Motley Fool
08:13AM  Merck agrees $1bn deal to buy biopharmaceutical company Peloton Financial Times
08:00AM  Celgene and the Multiple Sclerosis Association of America Team Up to Launch MS MindShift for Awareness of Multiple Sclerosis and Brain Health Business Wire
07:46AM  Alexion (ALXN) Stock Up 30.7% YTD: Will the Momentum Stay? Zacks
May-20-19 07:23PM  Prem Watsa Buys Buffett's Red Hat, Boosts Micron in 1st Quarter
06:43PM  George Soros' Top 6 New Buys of the 1st Quarter
06:32PM  4 New Stock Picks From Seth Klarman
02:28PM  Argus Questions Logic Behind Bristol-Myers' Proposed Celgene Buy, Steps To Sidelines Benzinga
09:16AM  Bristol-Myers Stock Is Falling Because the Celgene Merger May Not Make Sense
May-17-19 05:17PM  Celgene Gets EC Nod for Label Expansion of Revlimid, Imnovid Zacks
09:21AM  Q1 13F Roundup: How Buffett, Einhorn, Ackman And Others Adjusted Their Portfolios Benzinga
03:55AM  Carlson Capitals Latest Moves Insider Monkey
May-16-19 05:05PM  Seth Klarman Introduces 7 New Positions in 1st Quarter
10:49AM  Agios' Tibsovo Meets Endpoint in Cholangiocarcinoma Study Zacks
08:30AM  Celgene Receives European Commission Approvals for REVLIMID® (lenalidomide) and IMNOVID® (pomalidomide)-based Triplet Combination Regimens for Patients with Multiple Myeloma Business Wire
08:12AM  4 High Earnings Yield Stocks to Strengthen Your Portfolio Zacks
04:14AM  Adage Capital Managements Latest Portfolio Moves Insider Monkey
May-15-19 05:04PM  Celgene to Highlight New and Updated Hematology and Oncology Clinical Data at Upcoming American Society of Clinical Oncology (ASCO) 2019 Annual Meeting Business Wire
10:49AM  Biotech Stock Roundup: FDA Nod for REGN's Eylea in DR, Tie-Ups & Other Updates Zacks
07:50AM  The Daily Biotech Pulse: FDA Greenlights Pfizer-Merck KGAa's Kidney Cancer Combo Treatment, Adcom Disappointment For Daiichi Benzinga
May-13-19 01:03PM  Why Bristol-Myers Squibb's $19 Billion Debt Issuance to Buy Celgene Makes Sense
07:30AM  Celgene Corporation Announces POMALYST® Granted Breakthrough Therapy Designation from FDA for HIV-Positive and Negative Kaposi Sarcoma Business Wire
May-10-19 07:30AM  Lyfebulb and Celgene Announce Finalists for 2019 "Addressing Unmet Needs in MS: An Innovation Challenge" PR Newswire
May-09-19 10:07AM  Bristol-Myers Squibb's Opdivo Stumbles In Late-Stage Brain Cancer Study Benzinga
May-08-19 09:30AM  CELG vs. VRTX: Which Stock Should Value Investors Buy Now? Zacks
08:51AM  Prothena's (PRTA) Q1 Earnings Beat Estimates, Revenues Miss Zacks
08:12AM  bluebird bio Flies Forward Motley Fool
08:03AM  Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)? Zacks
07:00AM  Market Morning: Mylan Massacre, Futures Dither, Meatless McDonalds, Uber Drivers Bash Greed, Want More Money Market Exclusive
May-07-19 05:46PM  Bristol-Myers Borrows $19 Billion in Year's Biggest Bond Deal Bloomberg
01:54PM  Bristol-Myers Squibb Is Selling $19 Billion of Bonds to Buy Celgene
07:30AM  Analysis Showed Oral Ozanimod Reduced Brain Volume Loss Across All Age Subgroups in Adults with Relapsing Multiple Sclerosis Business Wire
02:59AM  Bristol-Myers Squibb in $19bn debt sale to fund Celgene deal Financial Times
May-06-19 04:53PM  Jerome Dodson Comments on Celgene
11:50AM  bluebird's (BLUE) Loss Wider Than Expected, Revenues Down Y/Y Zacks
08:13AM  3 Big Stock Charts for Monday: American Airlines Group, Mylan and Celgene InvestorPlace
May-03-19 01:08PM  Bristol-Myers Acquisition of Celgene Is a Prescription for Success, One Analyst Says
10:26AM  The Zacks Analyst Blog Highlights: Apple, Microsoft, General Electric, Ecolab and Celgene Zacks
10:19AM  Agios (AGIO) Earnings and Revenues Surpass Estimates in Q1 Zacks
06:00AM  Seattle life sciences industry has strength in numbers despite uncertainty American City Business Journals
May-02-19 03:08PM  Top Analyst Reports for Apple, Microsoft & General Electric Zacks
12:08PM  Bristol-Myers Squibb Company -- Moody's assigns A2 to Bristol-Myers's sr. notes; under review for downgrade Moody's
11:18AM  The Zacks Analyst Blog Highlights: Biogen, Celgene, Incyte, Alexion and Vertex Zacks
May-01-19 05:01PM  Celgene Corporation and bluebird bio Announce Results from Ongoing Multicenter Phase 1 Study of bb2121 anti-BCMA CAR T Cell Therapy in Patients with Multiple Myeloma Published in New England Journal of Medicine Business Wire
01:25PM  2020 hopeful John Hickenlooper says there won't be medicare for all right away Yahoo Finance Video
11:52AM  Biotech Stock Roundup: BIIB, VRTX, ALXN Q1 Earnings Top & Other Pipeline Updates Zacks
09:30AM  Is Celgene (CELG) Outperforming Other Medical Stocks This Year? Zacks
09:00AM  All You Need to Know About Celgene (CELG) Rating Upgrade to Buy Zacks
Apr-30-19 07:00PM  Top Biotech Stocks for February 2019 Investopedia
09:04AM  Can 'synthetic lethality' and deep experience propel this cancer-fighting biotech's $70M IPO? American City Business Journals
Apr-29-19 03:19PM  Celgene's Final Earnings Report? Motley Fool
11:29AM  3 Stocks Peter Lynch Would Love Motley Fool
Apr-26-19 01:44PM  Celgene (CELG) Q1 Earnings Beat Estimates on Revlimid Sales Zacks
07:30AM  Celgene Corporation and Acceleron Pharma Announce Submission of Luspatercept Marketing Authorization Application to the European Medicines Agency (EMA) for MDS and Beta-Thalassemia Business Wire
Apr-25-19 06:20PM  Celgene: 1Q Earnings Snapshot Associated Press
06:19PM  Celgene Earnings, Revenue Beat in Q1
05:38PM  Biotech Giant Celgene Tops First-Quarter Estimates As Bristol Buyout Looms Investor's Business Daily
04:37PM  Jerome Dodson's 1st Quarter Parnassus Endeavor Fund Commentary
04:30PM  Celgene Reports First Quarter 2019 Operating and Financial Results Business Wire
02:52PM  Bristol-Myers Q1 Earnings Beat, Sales Up on Strong Eliquis Zacks
02:45PM  Bristol-Myers Squibb Co (BMY) Q1 2019 Earnings Call Transcript Motley Fool
01:26PM  Bristol-Myers Squibb Earnings: BMY Stock Pops on Q1 Beat InvestorPlace
01:03PM  Bristol-Myers Squibb Posts Solid Q1 Results With the Celgene Acquisition Looming Motley Fool
11:15AM  Is a Beat in Store for Editas (EDIT) This Earnings Season? Zacks
09:48AM  Bristol-Myers Tops Q1 Earnings Estimate After Winning Celgene Takeover Approval
09:42AM  Bristol-Myers Squibb Beat Earnings Expectations as Sales of Blood-thinner Eliquis Jumped
09:24AM  The Zacks Analyst Blog Highlights: Celgene, Schlumberger, Becton, Dickinson, Twitter and PPG Industries Zacks
07:56AM  You can find plenty of solid stock bargains in this years worst-performing sector, analysts say MarketWatch
07:11AM  Bristol-Myers profit slightly tops Wall Street view on blood thinner sales Reuters
07:00AM  Bristol-Myers profit slightly tops Wall Street view on blood thinner sales Reuters
06:30AM  Bristol-Myers Squibb Reports Earnings Today. Heres What to Expect.
Apr-24-19 09:00PM  Bristol-Myers raises forecasts on strong sales of stroke and cancer drugs Financial Times
03:36PM  Top Analyst Reports for Celgene, Schlumberger & Becton, Dickinson Zacks
01:50PM  AbbVie and Bristol-Myers Squibb will report first-quarter earnings on Thursday. Heres what to expect MarketWatch
Apr-23-19 05:50PM  Celgene (CELG) Gains But Lags Market: What You Should Know Zacks
11:09AM  Why Is Bristol-Myers Near 52-Week Lows? InvestorPlace
09:27AM  What's in Store for Celgene Corporation (CELG) Q1 Earnings? Zacks
Apr-22-19 08:30AM  Will Bristol-Myers (BMY) Disappoint This Earnings Season? Zacks
Apr-20-19 05:00PM  How Marijuana Legalization Affected OrganiGram and Aphria's Latest Results Motley Fool
Apr-19-19 12:19PM  5 Top Biotech Stocks to Buy in 2019 Motley Fool
11:02AM  5 Top Healthcare Stocks to Buy in 2019 Motley Fool
Apr-17-19 12:11PM  Bristol-Myers Squibb Company -- Moody's assigns A2 to Bristol-Myers's exchange notes; under review for downgrade Moody's
08:18AM  Bristol-Myers Squibb Company Announces Commencement of Exchange Offers and Consent Solicitations for Celgene Notes Business Wire
07:48AM  Biotech Stock Roundup: GILD Collaborates on NASH, FCSC Surges on Deal Zacks
Apr-16-19 10:52AM  Why Amgen Stock Could Break Out to New Highs InvestorPlace
06:00AM  Why Celgene Shareholders Should Hold On to Their Bristol-Myers Squibb Stock Once the Acquisition Closes Motley Fool
Apr-15-19 05:54PM  David Rolfe Comments on Celgene
05:45PM  Celgene (CELG) Gains As Market Dips: What You Should Know Zacks
05:02PM  David Rolfe's Wedgewood Partners 1st-Quarter 2019 Client Letter
01:53PM  Bristol-Myers' Shareholders Vote for Celgene Acquisition Zacks
Apr-12-19 06:56PM  Bristol-Myers CEO: We're 'one step closer to creating that great company' with Celgene CNBC Videos
06:50PM  'One step closer to creating that great company' with Celgene, says Bristol-Myers CEO CNBC Videos
06:32PM  Bristol-Myers CEO: We're 'one step closer to creating that great company' with Celgene CNBC
01:21PM  Bristol-Myers says shareholders vote to approve Celgene takeover Reuters
11:11AM  Bristol-Myers Squibb Shareholders Approve Celgene Tie-Up
11:00AM  Bristol-Myers says shareholders vote to approve Celgene takeover Reuters
10:49AM  Bristol-Myers shareholders approve drugmaker's $74 billion deal with Celgene CNBC
10:33AM  Celgene Stockholders Approve Proposed Acquisition by Bristol-Myers Squibb Business Wire
07:23AM  Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)? Zacks
Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE to treat breast, non-small cell lung, pancreatic, and gastric cancers. The company's products also include IDHIFA for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (rrAML) with an isocitrate dehydrogenase-2 mutation; VIDAZA, a pyrimidine nucleoside analog for intermediate-2 and high-risk MDS, chronic myelomonocytic leukemia, and AML; THALOMID to treat patients with MM; and ISTODAX, an epigenetic modifier. Its preclinical and clinical-stage product candidates include small molecules, biologics, and cell therapies for immune-inflammatory diseases, myeloid diseases, epigenetics, protein homeostasis, and immuno-oncology. The company has agreements with BeiGene, Ltd; Acceleron Pharma, Inc.; Agios Pharmaceuticals, Inc.; bluebird bio, Inc.; Lycera Corp.; Juno Therapeutics, Inc.; and EXSCIENTIA LTD. Celgene Corporation was founded in 1980 and is headquartered in Summit, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Curran TerrieSEE REMARKSMay 02Option Exercise0.001,56309,483May 06 04:05 PM
VESSEY RUPERTSEE REMARKSMay 02Option Exercise0.006,731013,984May 06 04:05 PM
Alles Mark JCEO, CHAIRMAN OF BOARDMay 02Option Exercise0.0015,6080227,886May 06 04:05 PM
Biller JonathanEVP AND GENERAL COUNSELMay 02Option Exercise0.001,56304,674May 06 04:05 PM
AHMED NADIMPRES., HEMATOLOGY AND ONCOLOGYMay 02Option Exercise0.001,563013,124May 06 04:05 PM
Alles Mark JCEO, CHAIRMAN OF BOARDMar 01Option Exercise0.0033,8090226,178Mar 05 04:05 PM
LOUGHLIN JAMES JDirectorFeb 07Option Exercise22.4724,666554,24562,102Feb 11 04:05 PM
LOUGHLIN JAMES JDirectorFeb 07Sale87.2923,4662,048,32438,636Feb 11 04:05 PM
MARIO ERNESTDirectorDec 19Option Exercise59.068,600507,87363,013Dec 20 04:48 PM
Biller JonathanEVP AND GENERAL COUNSELDec 16Option Exercise0.001,90004,046Dec 18 06:45 PM
VESSEY RUPERTSEE REMARKSDec 16Option Exercise0.005,35009,887Dec 18 06:43 PM
Curran TerrieSEE REMARKSDec 16Option Exercise0.002,50009,151Dec 18 06:28 PM
AHMED NADIMPRES., HEMATOLOGY AND ONCOLOGYDec 16Option Exercise0.003,000013,038Dec 18 06:26 PM
Alles Mark JCEO, CHAIRMAN OF BOARDDec 16Option Exercise0.008,9290196,245Dec 18 06:25 PM
MARIO ERNESTDirectorNov 26Option Exercise59.0610,000590,55054,413Nov 28 04:05 PM
MARIO ERNESTDirectorAug 09Sale92.3212,0001,107,88844,413Aug 13 04:05 PM
BARKER RICHARD WDirectorJun 17Option Exercise0.001,000012,846Jun 18 04:00 PM
CASEY MICHAEL DDirectorJun 17Option Exercise0.0033400Jun 18 04:00 PM
Friedman Michael ADirectorJun 17Option Exercise0.0033400Jun 18 04:00 PM
LOUGHLIN JAMES JDirectorJun 17Option Exercise0.00334037,436Jun 18 04:00 PM
MARIO ERNESTDirectorJun 17Option Exercise0.00334056,413Jun 18 04:00 PM
Haller Julia ADirectorJun 15Option Exercise0.0037501,250Jun 15 04:57 PM
MARIO ERNESTDirectorJun 15Option Exercise0.00375056,079Jun 15 04:23 PM
Friedman Michael ADirectorJun 15Option Exercise0.002,41300Jun 15 04:12 PM
LOUGHLIN JAMES JDirectorJun 15Option Exercise0.002,441037,102Jun 15 04:13 PM
CASEY MICHAEL DDirectorJun 15Option Exercise0.0037500Jun 15 04:16 PM
BONNEY MICHAEL WDirectorJun 15Option Exercise0.0037501,050Jun 15 04:17 PM
BONNEY MICHAEL WDirectorJun 14Option Exercise0.003000675Jun 15 04:17 PM
CASEY MICHAEL DDirectorJun 14Option Exercise0.0030000Jun 15 04:16 PM
LOUGHLIN JAMES JDirectorJun 14Option Exercise0.00300034,661Jun 15 04:13 PM
Friedman Michael ADirectorJun 14Option Exercise0.0030000Jun 15 04:12 PM
MARIO ERNESTDirectorJun 14Option Exercise0.00300055,704Jun 15 04:23 PM
Haller Julia ADirectorJun 14Option Exercise0.003000875Jun 15 04:57 PM
COX CARRIE SMITHDirectorJun 12Option Exercise0.006,200030,080Jun 14 04:35 PM
CASEY MICHAEL DDirectorJun 07Option Exercise30.0127,750832,77827,750Jun 11 04:06 PM
CASEY MICHAEL DDirectorJun 07Sale78.7713,0001,024,0100Jun 11 04:06 PM
LOUGHLIN JAMES JDirectorJun 04Option Exercise30.0127,750832,77852,111Jun 05 04:15 PM
LOUGHLIN JAMES JDirectorJun 04Sale78.9617,7501,401,54034,361Jun 05 04:15 PM
Masoudi GeraldSEE REMARKSJun 01Option Exercise0.0015,000020,235Jun 05 04:09 PM